Mill Creek Capital Advisors LLC Has $1.29 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Mill Creek Capital Advisors LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 12.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,115 shares of the medical research company’s stock after purchasing an additional 442 shares during the period. Mill Creek Capital Advisors LLC’s holdings in Amgen were worth $1,286,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Aveo Capital Partners LLC boosted its position in shares of Amgen by 19.9% in the fourth quarter. Aveo Capital Partners LLC now owns 2,729 shares of the medical research company’s stock valued at $786,000 after acquiring an additional 453 shares during the period. Gryphon Financial Partners LLC boosted its position in shares of Amgen by 295.3% in the fourth quarter. Gryphon Financial Partners LLC now owns 3,684 shares of the medical research company’s stock valued at $1,021,000 after acquiring an additional 2,752 shares during the period. Cape Investment Advisory Inc. boosted its position in shares of Amgen by 4.9% in the fourth quarter. Cape Investment Advisory Inc. now owns 746 shares of the medical research company’s stock valued at $215,000 after acquiring an additional 35 shares during the period. Hilltop Holdings Inc. boosted its position in shares of Amgen by 53.0% in the fourth quarter. Hilltop Holdings Inc. now owns 6,921 shares of the medical research company’s stock valued at $1,993,000 after acquiring an additional 2,397 shares during the period. Finally, Mitchell Sinkler & Starr PA boosted its position in shares of Amgen by 26.0% in the fourth quarter. Mitchell Sinkler & Starr PA now owns 2,905 shares of the medical research company’s stock valued at $837,000 after acquiring an additional 600 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 0.5 %

NASDAQ:AMGN opened at $335.61 on Tuesday. Amgen Inc. has a twelve month low of $249.70 and a twelve month high of $346.85. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. The business has a 50 day moving average price of $329.68 and a two-hundred day moving average price of $306.47. The company has a market cap of $180.03 billion, a P/E ratio of 47.94, a price-to-earnings-growth ratio of 2.93 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The firm had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same period last year, the company earned $5.00 EPS. The company’s revenue was up 20.1% compared to the same quarter last year. As a group, analysts expect that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research note on Monday, September 16th. Jefferies Financial Group reissued a “buy” rating and set a $380.00 price objective (up from $375.00) on shares of Amgen in a report on Wednesday, August 7th. TD Cowen lifted their price objective on Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Argus lifted their price objective on Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Finally, Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Eleven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $327.28.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.